Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors.
about
Advances in small bowel neuroendocrine neoplasiaClinical utility of lanreotide Autogel® in gastroenteropancreatic neuroendocrine tumorsThe somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cellsNew therapeutic approaches to metastatic gastroenteropancreatic neuroendocrine tumors: A glimpse into the future.Phase II study of lanreotide autogel in Japanese patients with unresectable or metastatic well-differentiated neuroendocrine tumors.Therapy for metastatic pancreatic neuroendocrine tumors.Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0,Tyr3-octreotide versus 68Ga-DOTA0-lanreotide.Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study.Treatment of liver metastases in patients with neuroendocrine tumors: a comprehensive review.Effects of octreotide on glucose transporter type 2 expression in obese rat small intestine.Antitumor effects of somatostatin analogs in neuroendocrine tumors.Prognostic factors and characteristics of pancreatic neuroendocrine tumors: single center experiencePharmacotherapy of Zollinger-Ellison syndrome.A review of the use of somatostatin analogs in oncologyClinical-Pathological Conference Series from the Medical University of Graz : Case No 154: 32-year-old computer software engineer with nodular mass in the liver.Therapy of metastatic pancreatic neuroendocrine tumors (pNETs): recent insights and advancesTreatment of malignant pancreatic neuroendocrine neoplasms: middle-term (2-year) outcomes of a prospective observational multicentre study.Advances in the Treatment of Pancreatic Neuroendocrine Tumors (pNETs).Illuminating somatostatin analog action at neuroendocrine tumor receptorsUpdate on the management of gastroenteropancreatic neuroendocrine tumors with emphasis on the role of imaging.A review of systemic and liver-directed therapies for metastatic neuroendocrine tumors of the gastroenteropancreatic tract.Nonfunctional neuroendocrine tumor of the pancreas: Case report and review of the literature.Evolving treatment strategies for management of carcinoid tumors.Zollinger-Ellison syndrome: recent advances and controversies.The expanding role of somatostatin analogs in gastroenteropancreatic and lung neuroendocrine tumors.Somatostatin analogues in functioning gastroenteropancreatic neuroendocrine tumours: literature review, clinical recommendations and schedules.Synthesis and in vitro antitumor activity of new octapeptide analogs of somatostatin containing unnatural amino acids.Long-term disease control of a pancreatic neuroendocrine tumor with lanreotide autogel(®): a case report.Somatostatin analogues labeled with copper radioisotopes: current status.Anti-tumoral effects of somatostatin analogs: a lesson from the CLARINET study.Clinical and functional implication of the components of somatostatin system in gastroenteropancreatic neuroendocrine tumors.Disease Control on Lanreotide Autogel® 120 mg in a Patient with Metastatic Gastrinoma: A Case Report.Somatostatin receptor subtype 2 (sst₂) is a potential prognostic marker and a therapeutic target in medulloblastoma.Novel Somatostatin Receptor Ligands Therapies for Acromegaly.Octreotide lessens peritoneal injury in experimental encapsulated peritoneal sclerosis model.Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study
P2860
Q27000397-31B740B3-F65F-4917-BF38-4D03CEC752A0Q28069632-4416A551-2DB0-4AED-BB1A-AB5B04C0391EQ28484664-21185065-3ED1-448C-9184-A956D8EC7AFDQ30364864-6D64A9D8-0865-4BA5-8948-C92EA2804618Q33470421-897B9079-4DC0-4519-A4CE-F33F46926907Q34357869-787B23FE-9E5D-44DD-8430-5F7F34E886F6Q34477028-ACE1DBF2-8363-48D1-B95F-7FF86162DDADQ34992833-8DEE5F2F-74AB-44FB-B8E4-34EED9DA5BBFQ35371197-0F992B3A-A7E5-4730-BC77-734A74391951Q35555748-1AAE34D4-B4C6-4A12-B9AD-ACE559B57A80Q36051476-FC3C3128-64A2-4C16-AA13-BD6E14D37129Q36178121-948850E8-CBF0-4839-B8D0-65B734A24B6EQ36632665-96A88D5F-521E-4815-B680-9AD4389C0527Q36833161-966FA3F3-4F86-4BB7-A409-A272BA3C436FQ36885671-BCC53082-F1F0-4E9D-A91B-6B73E5813507Q37125550-03F5A824-90B6-40E3-9A0D-6D2E97B8DAD9Q37350299-3D5A775E-E20D-4FAE-948B-BDE8370A7E39Q37362261-33E62A89-4890-4DF8-AE42-6A278EB27FF4Q37443562-9EA9959D-5BEC-4FDE-BB91-03507E170012Q37673407-45EA7B95-B974-40C5-858D-641FE32CAA8DQ37859615-149BB329-5DE1-49ED-9B93-41A831E80E02Q38071445-5D3F5E2C-91AC-4DD1-8939-FE184AEB85AEQ38124702-84DB2023-71FB-4F40-8339-7D2A552FEF0CQ38150165-FAD4E92B-C36E-47CE-9138-C0C4F1D0AFFEQ38441413-94A227C9-FB9A-4E0C-835C-8DD8E11C1396Q38647297-2726F063-C136-4E42-AB1F-5BAA56960546Q38912617-397F0A35-E077-4CE4-AF49-85B3BBBFAF27Q41907580-684AD986-F0E7-407A-90F3-6FD0538F0413Q42133416-E5579372-4866-4DF6-B77F-FD687F8CA237Q47827757-02A9E0A0-69C5-48C3-B286-4210D54D0A33Q49352143-D36EAD9A-480B-4BB4-9D74-EF57D7B2B7DFQ50048308-7B3C8A36-AF4A-4981-ACF3-537DAD47DDF8Q50744249-1FDD5CBD-C08D-474B-931F-53E533F854E9Q52643700-0A1ADF7A-0FFF-477B-9C48-95B547165697Q53262915-FF71DEAA-4055-4C48-A8A1-C69541C12991Q57109641-958DF8E4-15E2-4250-9480-5A71E488894C
P2860
Antiproliferative effect of somatostatin analogs in gastroenteropancreatic neuroendocrine tumors.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Antiproliferative effect of so ...... creatic neuroendocrine tumors.
@en
Antiproliferative effect of so ...... creatic neuroendocrine tumors.
@nl
type
label
Antiproliferative effect of so ...... creatic neuroendocrine tumors.
@en
Antiproliferative effect of so ...... creatic neuroendocrine tumors.
@nl
prefLabel
Antiproliferative effect of so ...... creatic neuroendocrine tumors.
@en
Antiproliferative effect of so ...... creatic neuroendocrine tumors.
@nl
P2860
P356
P1476
Antiproliferative effect of so ...... creatic neuroendocrine tumors.
@en
P2093
Jonathan Strosberg
Larry Kvols
P2860
P304
P356
10.3748/WJG.V16.I24.2963
P407
P577
2010-06-01T00:00:00Z